Literature DB >> 13681024

Gastro-intestinal excretion of dextran-C14.

B ABERG, W L BLOOM, E HANSSON.   

Abstract

Entities:  

Keywords:  DEXTRAN/metabolism; GASTROINTESTINAL SYSTEM/metabolism

Mesh:

Substances:

Year:  1961        PMID: 13681024     DOI: 10.1111/j.1748-1716.1961.tb02217.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


× No keyword cloud information.
  9 in total

1.  USE OF DEXTRAN TO PREVENT ARTERIAL AND VENOUS THROMBOSIS.

Authors:  J A MONCRIEF; J C DARIN; P C CANIZARO; R B SAWYER
Journal:  Ann Surg       Date:  1963-10       Impact factor: 12.969

2.  Rat-intestinal dextranase. Localization and relation to the other carbohydrases of the digestive tract.

Authors:  A DAHLQVIST
Journal:  Biochem J       Date:  1963-01       Impact factor: 3.857

3.  [Pharmacocinetics and dosage of dextran 40 in relation to renal function (author's transl)].

Authors:  H Köhler; W Kirch; D Höffler; P Koeppe
Journal:  Klin Wochenschr       Date:  1974-12-01

4.  [The elimination of hydroxyethyl starch 200/0.5, dextran 40 and oxypolygelatine (author's transl)].

Authors:  H Köhler; H Zschiedrich; A Linfante; F Appel; H Pitz; R Clasen
Journal:  Klin Wochenschr       Date:  1982-03

5.  [Dosage and elimination of Dextran 40 in patients on hemodialysis (author's transl)].

Authors:  H Köhler; T R Weihrauch; P Fiegel; W Kirch; D Höffler
Journal:  Klin Wochenschr       Date:  1975-06-01

6.  [Prophylaxis and therapy of shunt thrombosis in terminal renal insufficiency (author's transl)].

Authors:  H Köhler
Journal:  Klin Wochenschr       Date:  1977-01-15

7.  Dextran administration avoids hemodynamic changes following paracentesis in cirrhotic patients. A safe and inexpensive option.

Authors:  R Terg; J Berreta; R Abecasis; G Romero; L Boerr
Journal:  Dig Dis Sci       Date:  1992-01       Impact factor: 3.199

8.  The isolation and properties of epithelial-cell "ghosts" from rat small intestine.

Authors:  B Clark; J W Porteous
Journal:  Biochem J       Date:  1965-08       Impact factor: 3.857

Review 9.  Clinical pharmacokinetic considerations in the use of plasma expanders.

Authors:  U Klotz; H Kroemer
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.